Abstract Library

#2246 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Characterisation of Prevalence and Prognosis in the Pulmonary Carcinoid Population

Introduction: DIPNECH is considered a rare condition and the natural history is poorly described. It is thought to give rise to pulmonary carcinoids (PCs) (>5mm) or tumourlets (≤5mm).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Hayes A

Authors: Hayes A, Banks J, Shah H, Luong T, Navalkissoor S,

Keywords: dipnech, diffuse idiopathic neuroendocrine cell hyperplasia, tumourlet, carcinoid, neuroendocrine tumor, multiple pulmonary nodules,

#2055 Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)

Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Laskaratos F, Shah R, Banks J, Smith J, Jacobs B,

Keywords: above-label somatostatin analogues, neuroendocrine tumor,

#1921 Prognostic Factors That Mandate Long Term Follow Up Following Surgery for Appendiceal Neuroendocrine Tumours (aNETs)

Introduction: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy and rarely recur. Current ENET guidelines inform their management and highlight areas of uncertainty.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Alabraba E, Banks M, Malik H, Fenwick S, Cuthbertson D,

Keywords: Appendix NET,

#550 Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy

Introduction: Y90-DOTATATE and Y90-DOTATOC are established treatments for patients with advanced neuroendocrine tumours. Outcomes associated with improved survival following therapy are still unclear.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Gilbert T, Mckane G, Banks M, Poston G, Vora J,

Keywords: Y90 DOTATOC/DOTATATE, survival,

#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease

Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Ardill J, Poston G,

Keywords: carcinoid disease, chromogranin A, Neurokinin A, N-Terminal Barin Naturetic Peptide, carcinoid heart disease, echocardiography,